And from the fourth quarter of 2013 to the second quarter of 2016, Mylan steadily raised EpiPen prices 15 percent every other quarter. The stock price more than tripled, going from $13.29 in 2007 to a high of $47.59 in 2016. And while sales …
Shares of Mylan N.V.’s MYL were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions. The company reported fourth-quarter 2016 earnings of $1.57 per …
One lower-price competitor, AdrenaClick, is not as widely available and some pharmacies that do stock the product charge around the same price as they do for EpiPen. Mylan has announced plans for a generic version of EpiPen, but the …
Daniel Zuchnik—WireImage By Julia Zorthian August 25, 2016 Actress Sarah Jessica Parker is ending her relationship with pharmaceutical giant Mylan and speaking out against ... spoke against the price hike and its stock plummeted …
A damning congressional report fresh off the press Tuesday (Sept. 20) connects the Clinton Foundation and three Indian drug companies – one of which was bought by Mylan NV (Nasdaq: MYL) a decade ago – to a humanitarian scandal…
What a difference a hostile takeover bid can make. Perrigo for months has been publicly trashing Mylan NV and its prospects as part of an effort to fend off a roughly $27 billion hostile bid from the Dutch company. Perrigo has told …
Shares of EpiPen maker Mylan (NASDAQ: MYL) surged 7 percent in morning trade Wednesday, on the heels of the company reporting fourth-quarter earnings that topped Wall Street's expectations. Mylan reported adjusted earnings …
NEW YORK (CNNMoney.com) -- Mylan Pharmaceuticals' stock plunged after the drugmaker said it was purchasing the generic arm of German drug giant Merck KGaA. Mylan (down $2.49 to $19.91, Charts) stock fell more than 13 percent …
Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports.